Superworth

Cellectar Biosciences EPS CLRB

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$4.60
Latest quarter, Q2 FY26
−$0.57
Fiscal year 2025
−$10.39

Cellectar Biosciences' earnings per share was −$4.60 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.57.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$10.39n/a
FY2024−$46.55n/a
FY2023−$108.30n/a
FY2022−$142.80n/a
FY2021−$131.40n/a
FY2020−$285.00n/a
FY2019−$600.00n/a
FY2018−$1842.00n/a
FY2017−$3159.00n/a
FY2016−$1050.00n/a
FY2015−$22230.00n/a
FY2014−$64200.00n/a
FY2013−$118800.00n/a
FY2012−$138000.00n/a
FY2011−$192000.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.57n/a−$4.60
Q1 FY26−$1.33n/a−$7.42
Q4 FY25−$1.29n/a−$10.39
Q3 FY25−$1.41n/a−$10.79
Q2 FY25−$3.39n/a−$21.51
Q1 FY25−$4.30n/a−$23.55
Q4 FY24−$1.69n/a−$46.55
Q3 FY24−$12.13n/a−$60.46
Q2 FY24−$5.43n/a−$94.83
Q1 FY24−$27.30n/a−$116.40
Q4 FY23−$15.60n/a−$108.30
Q3 FY23−$46.50n/a−$130.50

Against its peers

Companies in Drug Manufacturers - General nearest Cellectar Biosciences' size, closest first, today.

CompanyEPS, 12 monthsGrowth
CLRBCellectar Biosciences−$4.60
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Cellectar Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.